Verve Ventures
Verve Ventures is a European venture capital firm and startup investment platform headquartered in Switzerland. It operates a digital platform that connects qualified private investors, family offices and pension funds with startup opportunities, enabling access to private markets and portfolio diversification. Founded in 2010, the firm screens thousands of startups annually and backs a small subset after rigorous due diligence. A pan-European team supports portfolio companies and investor members with networking, hiring and strategic introductions, with offices in Zurich, Lausanne, Berlin, Paris and Cambridge. Verve Ventures focuses on science and technology, climate and energy, robotics and automation, data analytics, advanced manufacturing, clean energy infrastructure and digital health, investing from seed to growth stages across Europe. The platform and network together have funded hundreds of startups, and the firm continues to expand its ecosystem of private and institutional investors and entrepreneurs.
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Health Diagnostics
Aktiia
Series B in 2025
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
Orakl Oncology
Seed Round in 2024
Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.
Retinai
Series B in 2024
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Retinai
Series A in 2024
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Aktiia
Series A in 2024
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
Orakl Oncology
Seed Round in 2023
Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.
MedTrace Pharma
Venture Round in 2023
MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.
Therapixel
Series B in 2022
Therapixel develops and commercializes AI-based medical imaging software for surgeons, focusing on breast cancer detection and characterization and intraoperative image management. The company designs image analytics tools that enable clinicians to access and interpret medical images before or during procedures while maintaining sterility through touchless interfaces. Its product family includes Radvise, an automatic image reading solution; Fluid, a touchless medical image navigation system for surgery; Anywhere, a post-processing workstation; and CD-Feed, a CD import solution for outpatient imaging exams. Founded in 2013 and headquartered in Valbonne, France, Therapixel operates globally with a presence in multiple countries, supporting surgeons with timely, decision-ready imaging information.
SoterAI
Series A in 2022
Soter Analytics PTY LTD focuses on preventing musculoskeletal injuries in industrial workplaces through its innovative Soter Spine system, which combines wearable sensors and advanced analytics. The company provides devices that continuously monitor human movement, capturing health and locational data to identify at-risk movements and alert workers accordingly. By partnering with large industrial organizations, Soter integrates additional sensors, such as those for temperature and heart rate, to enhance safety and productivity. The company also offers an application that tracks long-term impacts and provides actionable recommendations for injury prevention. Founded in 2015 and based in Perth, Australia, Soter Analytics aims to set a new standard in workplace safety and ergonomics by leveraging AI-powered insights to foster a culture of safety and efficiency among workers.
Sleepiz
Series A in 2022
Founded in Zurich, Switzerland in 2018, Sleepiz develops a non-contact multidimensional sleep monitoring device. It tracks breathing, heart rate, and body movements with medical-grade accuracy, enabling diagnosis of sleep disorders and long-term patient-centric disease management.
Medimaps Group
Venture Round in 2021
Medimaps Group develops medical software that enhances osteoporosis diagnosis by assessing bone microarchitecture. Its AI-driven imaging tools help clinicians select appropriate treatments and monitor outcomes, with future applications in dental and orthopedic fields.
PathoQuest
Series B in 2021
PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.
Aktiia
Series A in 2021
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
Sleepiz
Series A in 2021
Founded in Zurich, Switzerland in 2018, Sleepiz develops a non-contact multidimensional sleep monitoring device. It tracks breathing, heart rate, and body movements with medical-grade accuracy, enabling diagnosis of sleep disorders and long-term patient-centric disease management.
EarlySight
Seed Round in 2021
EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.
Perfood
Series A in 2020
Founded in 2017, Perfood is a German digital therapeutics startup that offers personalized nutrition-based therapies via an application. It focuses on weight management and migraine prevention by analyzing sensor data, lab results, and holistic analyses to derive tailored therapeutic solutions.
Pregnolia
Series A in 2020
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.
Aktiia
Seed Round in 2020
Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.
OncoDNA
Series B in 2020
Founded by experts in DNA sequencing and diagnostic analyses in oncology, OncoDNA offers precision medicine solutions for cancer treatment. It provides clinical guidance for late-stage patients, supports research, and aids drug development.
Versantis
Series B in 2019
Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.
PathoQuest
Series A in 2019
PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.
Retinai
Seed Round in 2019
RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.
Piavita
Series A in 2019
Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.
Luciole Medical
Series A in 2018
Luciole Medical AG is a Swiss medical technology company that specializes in the design and manufacture of brain oxygenation monitoring systems. Founded in 2017 and based in Zurich, the company has developed a platform that accurately measures the levels of oxygenated and deoxygenated hemoglobin, as well as cerebral blood flow and other critical parameters. Its product lineup includes RheoPatch, a non-invasive sensor applied to the skin to assess oxygen metabolism and blood flow; RheoSens, an implantable probe that measures various cerebral metrics; RheoLity, which offers software for data display, analysis, and patient management; and RheoControl, which connects to medical monitors for data visualization. Luciole Medical's systems enable healthcare professionals to monitor cerebral oxygenation effectively, providing crucial insights into the patient's brain health.
Pregnolia
Seed Round in 2018
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.
Medyria
Series B in 2018
Medyria is a Swiss medtech company developing sensor-based catheter navigation and sensing systems for vascular, valve, and heart procedures. Its products include a sensor-based catheter positioning system for X-ray- and dye-free minimally invasive cardiovascular procedures, Flowcath for measuring blood flow, Trackcath for processing flow data and tracking catheters, and an OEM flow sensor for measuring blood or physiological fluid flow. The company uses proprietary Blood Flow Velocity Sensor technology to enable safer and more effective endovascular procedures by reducing procedural manipulations, duration, complications, and overall costs. Medyria is based in Winterthur, Switzerland.
DBS System
Series A in 2017
DBS System SA is a medtech company based in the Swiss Health Valley that specializes in the production of HemaXis™ blood collection devices. The company utilizes advanced microfluidic technology to create innovative devices designed for the less invasive, safer, and more efficient collection and preparation of blood samples. HemaXis devices facilitate plasma and serum extraction with precision and in a standardized format, significantly enhancing the capabilities of dried blood spot samples in bioanalysis. By streamlining blood collection processes, DBS System aims to support health monitoring and testing while contributing to the advancement of personalized medicine and big data initiatives.
Piavita
Seed Round in 2016
Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.
Medyria
Series A in 2015
Medyria is a Swiss medtech company developing sensor-based catheter navigation and sensing systems for vascular, valve, and heart procedures. Its products include a sensor-based catheter positioning system for X-ray- and dye-free minimally invasive cardiovascular procedures, Flowcath for measuring blood flow, Trackcath for processing flow data and tracking catheters, and an OEM flow sensor for measuring blood or physiological fluid flow. The company uses proprietary Blood Flow Velocity Sensor technology to enable safer and more effective endovascular procedures by reducing procedural manipulations, duration, complications, and overall costs. Medyria is based in Winterthur, Switzerland.
MEDUDEM
Seed Round in 2011
MEDUDEM Corp. is a company in the digital health sector that focuses on the improvement of collaboration and interaction of all participants involved around chronic diseases (CCM). On the basis of its readily available web- and mobile-based solutions Care Integrator® and Healthbrain®, MEDUDEM Corp. improves collaboration and exchanges between medical professionals and patients, as well as third-party organizations. This provides clear advantages and synergetic benefits for all parties in and around the healthcare market and ensures the interaction and communication in a simple, fast and comprehensive way and manner.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.